156 related articles for article (PubMed ID: 36712260)
1. Rate of atrial fibrillation and flutter induced tachycardiomyopathy in a cohort of hospitalized patients with heart failure and detection of indicators for improved diagnosis.
Ermert L; Kreimer F; Quast DR; Pflaumbaum A; Mügge A; Gotzmann M
Front Cardiovasc Med; 2022; 9():940060. PubMed ID: 36712260
[TBL] [Abstract][Full Text] [Related]
2. Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation.
Brembilla-Perrot B; Ferreira JP; Manenti V; Sellal JM; Olivier A; Villemin T; Beurrier D; De Chillou C; Louis P; Brembilla A; Juillière Y; Girerd N
Eur J Heart Fail; 2016 Apr; 18(4):394-401. PubMed ID: 26833591
[TBL] [Abstract][Full Text] [Related]
3. History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure.
Patel RB; Vaduganathan M; Rikhi A; Chakraborty H; Greene SJ; Hernandez AF; Felker GM; Redfield MM; Butler J; Shah SJ
JACC Heart Fail; 2019 Jan; 7(1):47-55. PubMed ID: 30409707
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.
Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP
Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489
[TBL] [Abstract][Full Text] [Related]
5. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Liu T; Zhang N; Tse G; Bazoukis G; Letsas K; Goudis C; Milionis H; Vrettos A; Korantzopoulos P
Heart Fail Rev; 2023 Jul; 28(4):925-936. PubMed ID: 36282460
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial.
Kalscheur MM; Saxon LA; Lee BK; Steinberg JS; Mei C; Buhr KA; DeMets DL; Bristow MR; Singh SN
Heart Rhythm; 2017 Jun; 14(6):858-865. PubMed ID: 28323173
[TBL] [Abstract][Full Text] [Related]
7. Impact of catheter ablation in patients with atrial flutter and concurrent heart failure.
Jani C; Arora S; Zuzek Z; Jaswaney R; Thakkar S; Patel HP; Lahewala S; Arora N; Josephson R; Deshmukh A; Viles-Gonzalez J; Osman MN; Sahadevan J; Hoit BD; Mackall JA
Heart Rhythm O2; 2021 Feb; 2(1):53-63. PubMed ID: 34113905
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter.
Ahmari SA; Bunch TJ; Chandra A; Chandra V; Ujino K; Daly RC; Kushwaha SS; Edwards BS; Maalouf YF; Seward JB; McGregor CG; Chandrasekaran K
J Heart Lung Transplant; 2006 Jan; 25(1):53-60. PubMed ID: 16399531
[TBL] [Abstract][Full Text] [Related]
9. Heart failure and the risk of left atrial thrombus formation in patients with atrial fibrillation or atrial flutter.
Wybraniec MT; Mizia-Szubryt M; Cichoń M; Wrona-Kolasa K; Kapłon-Cieślicka A; Gawałko M; Budnik M; Uziębło-Życzkowska B; Krzesiński P; Starzyk K; Gorczyca-Głowacka I; Daniłowicz-Szymanowicz L; Kaufmann D; Wójcik M; Błaszczyk R; Hiczkiewicz J; Łojewska K; Kosmalska K; Fijałkowski M; Szymańska A; Wiktorska A; Haberka M; Kucio M; Michalski B; Kupczyńska K; Tomaszuk-Kazberuk A; Wilk-Śledziewska K; Wachnicka-Truty R; Koziński M; Burchardt P; Mizia-Stec K
ESC Heart Fail; 2022 Dec; 9(6):4064-4076. PubMed ID: 36039813
[TBL] [Abstract][Full Text] [Related]
10. 20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units.
Gavina C; Carvalho DS; Valente F; Bernardo F; Dinis-Oliveira RJ; Santos-Araújo C; Taveira-Gomes T
J Cardiovasc Dev Dis; 2022 May; 9(5):. PubMed ID: 35621860
[TBL] [Abstract][Full Text] [Related]
11. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
Vaduganathan M; Piccini JP; Camm AJ; Crijns HJGM; Anker SD; Butler J; Stewart J; Braceras R; Albuquerque APA; Wieloch M; Hohnloser SH
Eur J Heart Fail; 2022 Jun; 24(6):1094-1101. PubMed ID: 35293087
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis.
Wang M; Zhang Y; Wang Z; Liu D; Mao S; Liang B
J Thorac Dis; 2022 May; 14(5):1620-1637. PubMed ID: 35693625
[TBL] [Abstract][Full Text] [Related]
13. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Outcomes of Concurrently Diagnosed New Rapid Atrial Fibrillation or Flutter and New Reduced Ejection Fraction.
Rodriguez Y; Althouse AD; Adelstein EC; Jain SK; Mendenhall GS; Saba S; Shalaby AA; Voigt AH; Wang NC
Pacing Clin Electrophysiol; 2016 Dec; 39(12):1394-1403. PubMed ID: 27868213
[TBL] [Abstract][Full Text] [Related]
15. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
[No Abstract] [Full Text] [Related]
16. Atrial flutter or fibrillation is the most frequent and life-threatening arrhythmia in myotonic dystrophy.
Brembilla-Perrot B; Schwartz J; Huttin O; Frikha Z; Sellal JM; Sadoul N; Blangy H; Olivier A; Louis S; Kaminsky P
Pacing Clin Electrophysiol; 2014 Mar; 37(3):329-35. PubMed ID: 24117873
[TBL] [Abstract][Full Text] [Related]
17. CHA
Rutland J; Ayoub K; Etaee F; Ogunbayo G; Darrat Y; Marji M; Masri A; Elayi CS
Int J Cardiol; 2021 Jan; 323():72-76. PubMed ID: 32800906
[TBL] [Abstract][Full Text] [Related]
18. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.
Slee A; Saad M; Saksena S
J Interv Card Electrophysiol; 2019 Sep; 55(3):325-331. PubMed ID: 30887281
[TBL] [Abstract][Full Text] [Related]
19. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
Piccini JP; Connolly SJ; Abraham WT; Healey JS; Steinberg BA; Al-Khalidi HR; Dignacco P; van Veldhuisen DJ; Sauer WH; White M; Wilton SB; Anand IS; Dufton C; Marshall DA; Aleong RG; Davis GW; Clark RL; Emery LL; Bristow MR
Am Heart J; 2018 May; 199():51-58. PubMed ID: 29754666
[TBL] [Abstract][Full Text] [Related]
20. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
Sobue Y; Watanabe E; Lip GYH; Koshikawa M; Ichikawa T; Kawai M; Harada M; Inamasu J; Ozaki Y
Heart Vessels; 2018 Apr; 33(4):403-412. PubMed ID: 29067492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
